Compare Novo Nordisk A/S (NVO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Novo Nordisk A/S trades at $38.15 (market cap $165.31B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.9 (market cap $3.39B). The key difference: Novo Nordisk A/S is far larger — about 48.8× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| NVO | SPUS | |
|---|---|---|
Market Cap | $165.31B | $3.39B |
Volume | 11,432,838 | 349,184 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $61.15 |
52-Week Low | $35.29 | $46.65 |
Typical Hold Time | 116 Days | 64 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
